DOCSLIB.ORG

Tinea) Versicolor (1 of 4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tinea) Versicolor (1 of 4 Pityriasis (Tinea) Versicolor (1 of 4) 1 Patient presents w/ various colored macules (hyper- or hypopigmented, erythematous) w/ fine scales suggestive of pityriasis (tinea) versicolor 2 DIAGNOSIS Do clinical presentation & No ALTERNATIVE microscopy confirm DIAGNOSIS tinea versicolor? Yes A Patient education B Pharmacological therapy Topical Antifungals Any one of the following: • Ketoconazole • Imidazole • Butenafi ne • Ciclopirox • Tolnaftate • Naftifi ne • Selenium sulfi de • Terbinafi ne Oral Antifungals (consider for severe or widespread disease) Any one of the following: • Fluconazole • Itraconazole • Ketoconazole © MIMS Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B190 © MIMS Pediatrics 2019 Pityriasis (Tinea) Versicolor (2 of 4) 1 CLINICAL PRESENTATION • Common, benign, superfi cial fungal infection localized to the stratum corneum - Occurs most commonly in postpubertal individuals when the sebaceous glands are the most active • Facial involvement is common in adolescents, but lesions are also found on the upper trunk, neck, arms, dorsum of the hand & pubis - Although sometimes it is generalized • Patient presents w/ erythematous, hypo- or hyperpigmented macules or patches that may have a slight scale - Pruritus may or may not be present • Lesions do not tan along w/ surrounding normal skin PITYRIASIS (TINEA) VERSICOLOR PITYRIASIS • Caused by lipophilic yeast Malassezia spp & M. furfur is the most common 2 DIAGNOSIS Microscopy • Potassium hydroxide (KOH) examination of skin scrapings should confi rm the diagnosis - Scales or debris are mounted in 10-15% KOH soln & viewed under light microscope - Short stubby hyphae & yeast cells will be visible (appears as “spaghetti & meatballs”) Culture • Culture is not usually helpful because Malassezia spp is diffi cult to grow as it is part of the normal fl ora Wood’s Light Exam • Malassezia spp shows pale yellow to white fl uorescence on Wood’s light exam Alternative Diagnosis • Other conditions w/ similar appearance as tinea versicolor include seborrheic dermatitis, secondary syphilis, & pityriasis alba A PATIENT EDUCATION • Educate patient about the basics of yeast growth - Causative agent is not eliminated from the skin & recurrence occurs in susceptible individuals - Malassezia spp are lipophilic; advise patient to avoid oils applied to the skin or in the bath Factors that Promote Tinea Versicolor Infection: • High temperature & high humidity - Prominent in tropical & subtropical regions • Occlusive clothing • Oily skin • Application of oils to skin • Excessive sweating • Immunocompromise conditions, malnutrition & hereditary predisposition • High levels of plasma cortisol B PHARMACOLOGICAL THERAPY • Condition chronically recurs in predisposed patients despite adequate initial treatment • Skin discoloration may take several wk to resolve after complete treatment Topical Antifungals • E ff e c t : Topical treatments are typically eff ective in temporarily eradicating the disease Selenium Sulfi de & Imidazoles • ese agents are equally eff ective w/ 60-80% recurrence rate Oral Antifungals • Oral therapy is indicated in cases of severe or widespread skin involvement, recurrent infections & failure of topical therapy • Oral therapy can be convenient & less time consuming enhancing patient compliance • Eff ect: Infection© recurrence may occur MIMSless frequently if treated w/ oral antifungals Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B191 © MIMS Pediatrics 2019 Pityriasis (Tinea) Versicolor (3 of 4) Dosage Guidelines ANTIFUNGALS (ORAL) Drug Dosage Remarks Fluconazole <2 wk: 3-6 mg/kg PO 72 hrly Adverse Reactions 2-4 wk: 3-6 mg/kg PO 48 hrly • GI eff ects (abdominal pain, N/V, diarrhea); Other PITYRIASIS (TINEA) VERSICOLOR PITYRIASIS >4 wk: 3-6 mg/kg PO 24 hrly eff ects (headache, insomnia, palpitations, pruritus, Max dose: 12 mg/kg/day sweating, fever, elevated serum transaminases) Itraconazole 100-200 mg PO 24 hrly x 5-7 days Adverse Reactions • GI eff ects (N/V, diarrhea, abdominal pain); Hepatic eff ects (elevation of serum transaminases, hepatitis & jaundice if treatment >1 mth); Other eff ects (headache, dizziness, pruritus, heart failure) Ketoconazole 15-30 kg: 100 mg PO 24 hrly Adverse Reactions >30 kg: 200 mg PO 24 hrly • GI eff ects (N/V, abdominal pain); Other eff ects (rashes, urticaria, itching, headache) • Rarely angioedema, paresthesia, thrombocytopenia, photophobia, dizziness, alopecia, gynecomastia, oligospermia, fatal liver damage - Risk of liver damage increases if given for >14 days ANTIFUNGALS (TOPICAL) Available Drug Strength Dosage Remarks Imidazoles Bifonazole 1% soln, cream Apply 24 hrly Adverse Reactions • Clotrimazole1 1% soln, lotn, Apply 8-12 hrly Occasional local irritation & cream, spray, hypersensitivity reactions, mild powd 2% cream burning, erythema & pruritus Special Instructions Econazole1 1% cream Apply 8-12 hrly • Treat for 2-3 wk unless otherwise stated Isoconazole 1% cream Apply 24 hrly Ketoconazole 2% gel, cream, Apply 12-24 hrly spray 1% scalp soln Apply & rinse off 24 hrly 2% soln,scalp x 5 days or soln Apply & rinse off twice wkly x 2-4 wk 2% shampoo Apply & rinse off after 3-5 min 24 hrly x 5 days 1Various strengths© & combinations w/ corticosteroids MIMS are available. Specifi c prescribing information may be found in the latest MIMS. All dosage recommendations are for children w/ normal renal & hepatic function unless otherwise stated. Not all products are available or approved for above use in all countries. Products listed above may not be mentioned in the disease management chart but have been placed here based on indications listed in regional manufacturers’ product information. Specifi c prescribing information may be found in the latest MIMS. B192 © MIMS Pediatrics 2019 Pityriasis (Tinea) Versicolor (4 of 4) Dosage Guidelines ANTIFUNGALS (TOPICAL) (CONT’D) Available Drug Strength Dosage Remarks Imidazoles (Cont’d) Miconazole 2% soln, tinct, Apply 12 hrly Adverse Reactions PITYRIASIS (TINEA) VERSICOLOR PITYRIASIS cream • Occasional local irritation & Sertaconazole 2% cream Apply 12-24 hrly hypersensitivity reactions, mild burning, erythema & pruritus Tioconazole 1% soln, cream, Apply 12-24 hrly Special Instructions lotn • Treat for 2-3 wk unless otherwise stated Other Antifungals Amorolfi ne 0.25% cream Apply 24 hrly x 2-3 wk Adverse Reactions • Erythema, pruritus, slight burning sensation Butenafi ne 1% cream Apply 24 hrly x 2-4 wk Adverse Reactions • Contact dermatitis, burning/ stinging sensation, erythema, irritation, itching Ciclopirox 1.5% liqd soap Apply & rinse after 3-5 min, Adverse Reactions ( Ciclopiroxolamine, 2-3x/wk • Pruritus, redness, burning, pain Ciclopirox olamine) Naftifi ne 1% cream Apply 24 hrly Adverse Reactions • Burning/stinging sensation, erythema, pruritus Salicylic acid1 3% bar, 4% tinct Apply 8-12 hrly Adverse Reactions • Skin irritation Selenium sulfi de 2.5% lotn, Apply & rinse off after Adverse Reactions shampoo, susp 5-10 min 24 hrly x 7 days • Occasionally local irritation, To prevent recurrence: hypersensitivity, mild burning, Apply & rinse off after erythema, pruritus 5-10 min once a mth Terbinafi ne 1% soln, cream, Apply 12 hrly x 1-2 wk Adverse Reactions gel, spray • Redness, stinging, itching, rarely allergic reactions Tolnaftate 1% soln, cream, Apply 8-12 hrly x 2-3 wk Adverse Reactions oint • Irritation, stinging, pruritus, contact dermatitis 1Various strengths & combinations of salicylic acid are available. Specifi c prescribing information may be found in the latest MIMS. All dosage recommendations are for children w/ normal renal & hepatic function unless otherwise stated. ©Not all products areMIMS available or approved for above use in all countries. Products listed above may not be mentioned in the disease management chart but have been placed here based on indications listed in regional manufacturers’ product information. Specifi c prescribing information may be found in the latest MIMS. Please see the end of this section for the reference list. B193 © MIMS Pediatrics 2019.
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • New Insights Into the Effect of Amorolfine Nail Lacquer
    Review article New insights into the effect of amorolfine nail lacquer C. Flagothier, C. Pie´ rard-Franchimont and G. E. Pie´ rard Department of Dermatopathology, University Hospital of Lie`ge, Lie`ge, Belgium Summary Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains uncertain. Several factors account for treatment failure, of which the pharmacokinetics and pharmacodynamics of the antifungal are of importance. The taxonomic nature and ungual location of the fungus cannot be neglected, besides the type of nail and its growth rate. In addition, the biological cycle of the fungus and the metabolic activity of the pathogen likely play a marked influence in drug response. The presence of natural antimicrobial peptides in the nail is also probably a key feature controlling the cure rates. There are many outstanding publications that cover the full spectrum of the field. The purpose of this review is to put in perspective some facets of activity of the topical treatment using amorolfine nail laquer. The antifungal activity of the drug is likely less pronounced in onychomycosis than that expected from conventional in vitro studies. However, the nail laquer formulation should reduce the propensity to form antifungal-resistant spores and limit the risk of reinfection. Key words: amorolfine, antifungal, fungus, onychomycosis, spore. Topical treatments are often considered to be less Introduction efficacious than current oral treatments. However, some During the last 2 decades, the efficacy of treating topical formulations may provide effects that cannot be onychomycoses has been considerably improved by achieved by other treatments. In discussing the treat- the introduction of new generations of potent antifun- ment of onychomycosis, it should not be forgotten that gals.
    [Show full text]
  • Comparison of Efficacy of Combination of 2% Ketoconazole
    Open Access Original Article Comparison of Topical Treatments in Pityriasis Versicolor Pak Armed Forces Med J 2018; 68 (6): 1725-30 COMPARISON OF EFFICACY OF COMBINATION OF 2% KETOCONAZOLE SOLUTION WASH AND TOPICAL 1% CLOTRIMAZOLE WITH TOPICAL 1% CLOTRIMAZOLE ALONE IN CASES OF PITYRIASIS VERSICOLOR Ayesha Anwar, Naeem Raza, Najia Ahmed, Hyder Ali Awan* Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan, *King Abdul Aziz Naval Base, Jubail, Saudia Arabia ABSTRACT Objective: Comparison of efficacy of combination comprising 2% ketoconazole solution wash plus topical 1% clotrimazole versus topical 1% clotrimazole alone in management of patients with Pityriasis versicolor. Study Design: Randomized controlled trial. Place and Duration of Study: Dermatology department, Pak Emirates Military Hospital Rawalpindi, from Oct 2016 to Apr 2017. Material and Methods: Sixty patients of Pityriasis versicolor, both male and female were included in study. Diagnosis of Pityriasis versicolor was made clinically and confirmed microscopically by examining skin scrapings for fungal hyphae. Patients with concomitant systemic illnesses or those who had received anti-fungal in last three months were excluded from study. Random number tables were used to allocate patients to the two treatment groups. Group A received 2% ketoconazole shampoo twice per week for four weeks plus topical 1% clotrimazole twice daily application for 2 weeks. Group B received only topical therapy with 1% clotrimazole cream applied twice daily for 2 weeks. Assessment of treatment efficacy was done by clinical examination of patient and microscopy of skin scrapping for fungal hyphaedone at baseline and at end of study (4 weeks of treatment). A negative clinical examination and negative skin scrapping for fungal hyphae was considered effective therapeutic response.
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Step Therapy Criteria Drug Class Topical Antifungal Agents (Brand Products Only)
    STEP THERAPY CRITERIA DRUG CLASS TOPICAL ANTIFUNGAL AGENTS (BRAND PRODUCTS ONLY) BRAND NAME (generic) ECOZA (econazole) ERTACZO (sertaconazole) EXELDERM (sulconazole nitrate) LOPROX (ciclopirox shampoo) LOTRISONE (clotrimazole/betamethasone) LUZU (luliconazole) MENTAX (butenafine) NAFTIN (naftifine) OXISTAT (oxiconazole) VUSION (miconazole/zinc oxide/white petrolatum) XOLEGEL (ketoconazole) Antifungal Topical Step Therapy Policy 06-2017 CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). ® Registered trademark of the Blue Cross and Blue Shield Association Page 1 of 4 Status: CVS Caremark Criteria Type: Initial Step Therapy; Post Step Therapy Prior Authorization POLICY FDA-APPROVED INDICATIONS Ecoza Ecoza topical 1% foam is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton
    [Show full text]
  • Comparison of Topical Anti- Fungal Agents Sertaconazole And
    DOI: 10.7860/JCDR/2014/10210.4866 Original Article Comparison of Topical Anti- Fungal Agents Sertaconazole and Pharmacology Section Clotrimazole in the Treatment of Tinea Corporis-An Observational Study RAGHU PRASADA MALLADAR SHIVAMURTHY1, SHASHIKALA GOWDARA HANUMANTAPPA REDDY2, RAVINDRA KALLAPPA3, SHANKAR ACHAR SOMASHEKAR4, DEEPA PATIL5, UMAKANT N PATIL6 ABSTRACT Results: The total score included all grades in erythema, Objectives: To compare the efficacy of topical antifungal agents, itching, scaling, margins and size of lesion and KOH mount. Sertaconazole and Clotrimazole in Tinea corporis patients. There was significant reduction in erythema (p<0.02) and highly significant reduction in scaling (p<0.001), itching (p<0.001) and Materials and Methods: A total of 60(n=60) patients were margins of lesion (p<0.001) among Sertaconazole group. The included in the study. They were divided into two groups of mean difference and the standard deviation of total scores for 30 patients each. First group included patients treated with Clotrimazole were 7.20 and 1.69 and for Sertaconazole group topical Sertaconazole as test drug whereas the second group 8.80 and 1.52 respectively. The p-value on application of constituted patients treated with topical Clotrimazole as students unpaired t- test was p<0.001 (Highly significant). standard drug. The patients were advised to apply the drug on affected area twice daily for three weeks. The parameters like Conclusion: From the present study, it can be concluded that erythema, scaling, itching, margins and size of the lesion and topical Sertaconazole shows better improvement in the clinical KOH mount were taken for the assessment of efficacy.
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Oral Antifungals Month/Year of Review: July 2015 Date of Last
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update with New Drug Evaluation: Oral Antifungals Month/Year of Review: July 2015 Date of Last Review: March 2013 New Drug: isavuconazole (a.k.a. isavunconazonium sulfate) Brand Name (Manufacturer): Cresemba™ (Astellas Pharma US, Inc.) Current Status of PDL Class: See Appendix 1. Dossier Received: Yes1 Research Questions: Is there any new evidence of effectiveness or safety for oral antifungals since the last review that would change current PDL or prior authorization recommendations? Is there evidence of superior clinical cure rates or morbidity rates for invasive aspergillosis and invasive mucormycosis for isavuconazole over currently available oral antifungals? Is there evidence of superior safety or tolerability of isavuconazole over currently available oral antifungals? • Is there evidence of superior effectiveness or safety of isavuconazole for invasive aspergillosis and invasive mucormycosis in specific subpopulations? Conclusions: There is low level evidence that griseofulvin has lower mycological cure rates and higher relapse rates than terbinafine and itraconazole for adult 1 onychomycosis.2 There is high level evidence that terbinafine has more complete cure rates than itraconazole (55% vs. 26%) for adult onychomycosis caused by dermatophyte with similar discontinuation rates for both drugs.2 There is low
    [Show full text]
  • Evaluation of the Drug Treatment and Persistence of Onychomycosis
    Review TheScientificWorldJOURNAL (2004) 4, 760–777 ISSN 1537-744X; DOI 10.1100/tsw.2004.134 Evaluation of the Drug Treatment and Persistence of Onychomycosis Andrew W. Campbell1, Ebere C. Anyanwu2,*, and Mohammed Morad3 1Medical Center for Immune and Toxic Disorders, 20510 Oakhurst Drive, Suite 200, Spring TX; 2Neurosciences Research, Cahers Inc., 8787 Shenandoah Park Drive, Suite 122, Conroe, Houston, 77385 TX; 3Clalit Health Services and Division of Community Health, Department of Family Medicine, Ben Gurion University, Beer-Sheva, Israel E-mail: [email protected] Received August 1, 2004; Revised August 18, 2004; Accepted August 19, 2004; Published August 31, 2004 Onychomycosis is a common nail disease responsible for approximately 50% of diseases of the nail. It occurs more in the elderly, though several cases have been reported among children. Several factors influence, such as climate, geography, and migration. The two dermatophytes most commonly implicated in onychomycosis are Trichophyton rubrum and T. mentagrophytes, accounting for more than 90% of onychomycoses. Nonetheless, several other toxigenic molds have been implicated. For convenience, onychomycosis is divided into four major clinical presentations: distal subungal, which is the most common form of the disease; proximal subungal, which is the most common form found in patients with human immunodeficiency virus infection; superficial; and total dystrophic onychomycosis. Epidemiology of onychomycosis in adults and children is evaluated and the most common clinical symptoms addressed. Although the risk factors are discussed, the multifactorial nature of onychomycosis makes this inexhaustible. The diagnosis and treatments are difficult and the choice of appropriate antifungal drugs complex and require the knowledge of the chemical structures of the metabolites of the molds that cause onychomycosis and their interaction with the antifungal drugs.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]